Analysts Set Phibro Animal Health Corporation (NASDAQ:PAHC) Price Target at $20.80

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) has received an average recommendation of "Reduce" from the six ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.80.

A number of research firms have recently weighed in on PAHC. Morgan Stanley upped their price objective on Phibro Animal Health from $20.00 to $21.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. BNP Paribas raised Phibro Animal Health to a "hold" rating in a research note on Monday. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research note on Monday. Finally, Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th.

Hedge Funds Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in Phibro Animal Health during the first quarter valued at approximately $10,312,000. Invesco Ltd. raised its position in Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company's stock valued at $8,282,000 after purchasing an additional 186,087 shares during the period. Axecap Investments LLC purchased a new stake in Phibro Animal Health during the first quarter valued at approximately $3,696,000. Millennium Management LLC raised its position in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company's stock valued at $7,733,000 after purchasing an additional 154,281 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its position in Phibro Animal Health by 56.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 301,173 shares of the company's stock valued at $6,325,000 after purchasing an additional 108,918 shares during the period. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC traded down $0.49 during mid-day trading on Monday, reaching $23.96. The company's stock had a trading volume of 215,002 shares, compared to its average volume of 207,130. The firm has a market capitalization of $971.10 million, a PE ratio of 30.72, a P/E/G ratio of 0.46 and a beta of 0.74. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The stock has a fifty day moving average of $21.59 and a two-hundred day moving average of $21.92. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $26.55.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. The firm had revenue of $347.80 million during the quarter, compared to analyst estimates of $352.41 million. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. As a group, sell-side analysts anticipate that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Wednesday, June 4th will be paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date is Wednesday, June 4th. Phibro Animal Health's payout ratio is presently 61.54%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.